Evidence map›Paper›PMID 38650830›Full record

ArticleBrain communications2024

γ-Aminobutyric acid transporter and GABA

Wangzhen Shen, Gerald Nwosu, Michael Honer, Jerome Clasadonte, Svenja Schmalzbauer, Marshall Biven, Katherine Langer, Carson Flamm, Sarah Poliquin, Felicia Mermer and 3 more

Open access · goldAbstract read
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. 4-Phenylbutyrate Rescue inbioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Wangzhen ShenDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Gerald NwosuDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Michael HonerPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel 4070, Switzerland.
Jerome ClasadonteEarly Solutions, Neuroscience TA, UCB Biopharma SRL, Braine l'Alleud 1420, Belgium.
Svenja SchmalzbauerPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel 4070, Switzerland.
Marshall BivenDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Katherine LangerDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Carson FlammDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Sarah PoliquinNeuroscience Graduate Program, Vanderbilt University, Nashville, TN 37232, USA.ORCID https://orcid.org/0000-0002-4151-3991
Felicia MermerDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Stefanie DedeurwaerdereEarly Solutions, Neuroscience TA, UCB Biopharma SRL, Braine l'Alleud 1420, Belgium.
Maria-Clemencia HernandezPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel 4070, Switzerland.
Jing-Qiong KangDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID https://orcid.org/0000-0003-1079-5436
Vanderbilt University Medical Center · USRoche (Switzerland) · CHUCB Pharma (Belgium) · BEVanderbilt University · USMeharry Medical College · US

Funding

Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
Promoting Protein Trafficking with 4-phenylbutyrate to Treat Genetic EpilepsyR01NS121718 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jing-Qiong Kang · 2022 to 2026
$2.2M
NICHD NIH HHS P50 HD103537NINDS NIH HHS R01 NS121718
6 · The paper itself

Abstract

We have previously characterized the molecular mechanisms for variants in γ-aminobutyric acid transporter 1-encoding solute carrier family 6-member 1 (

Indexed as

endoplasmic reticulum retentionepilepsyGABAA receptors (GABAARs)GABA transporter 1 (GAT-1)neurodevelopmental delay

Identifiers

PMID38650830
PMCPMC11032196
OpenAlexW4394974977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.